Back to search

Article

An inducible BRCA1 expression system with <i>in vivo</i> applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance

2025-08-07

Abstract excerpt

Poly(ADP-ribose) polymerase inhibitors (PARPi) have transformed cancer therapy for patients harbouring homologous recombination repair (HRR) deficiencies, notably BRCA1/2 mutations. However, resistance to PARPi remains a clinical challenge, with restoration of BRCA1 function via hypomorphic variants representing an understudied scenario. Here, we engineered a doxycycline-inducible BRCA1 expression system in the BR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c51caa32-8a27-54ec-b199-f2f75c6c48a4
DOI
10.1101/2025.08.05.668495
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
An inducible BRCA1 expression system with <i>in vivo</i> applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistanceDOI 10.1101/2025.08.05.668495
Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistanceSemantic proximity
Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcomaSemantic proximity
Mutational and functional heterogeneity of homology-directed repair deficiency and clinical implicationsSemantic proximity
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistanceSemantic proximity
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatmentSemantic proximity
Impact of homologous recombination deficiency on CDK4/6 inhibitor sensitivity in HR+/HER2-breast cancerSemantic proximity
Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.Semantic proximity
Therapeutic vulnerability to PARP1/2 inhibition in <i>RB1</i> -mutant osteosarcomaSemantic proximity
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.Semantic proximity
Resistance to therapy caused by intragenic deletion in BRCA2.Semantic proximity
A meta-analysis of clinical cases of reversion mutations in <i>BRCA</i> genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistanceSemantic proximity
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceSemantic proximity
Select a neighboring publication to make it the new centre.